206. Fragile X syndrome
98 clinical trials,   73 drugs   (DrugBank: 27 drugs),   46 drug target genes,   57 drug target pathways

Searched query = "Fragile X syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-000251-89-BE
(EUCTR)
22/10/201418/08/2014A clinical study with an investigational drug called ganaxolone in children with fragile X syndromeA controlled double-blind crossover trial of ganaxolone in children with fragile X syndrome - GNX study behavioral problems in children with fragile X syndrome
MedDRA version: 17.0;Level: PT;Classification code 10017324;Term: Fragile X syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Ganaxolone
Product Code: CCD 1042, MD 9150000, Mepalon 1042, SPT316
INN or Proposed INN: GANAXOLONE
Antwerp University HospitalNULLNot RecruitingFemale: yes
Male: yes
60United States;Belgium
2NCT01725152
(ClinicalTrials.gov)
November 20127/11/2012Ganaxolone Treatment in Children With Fragile X SyndromeA Controlled, Double-blind, Crossover Trial of Ganaxolone in Children With Fragile X SyndromeFragile x SyndromeDrug: Ganaxolone;Drug: PlaceboMarinus PharmaceuticalsUniversity of California, Davis;U.S. Army Medical Research and Development CommandCompleted6 Years17 YearsAll59Phase 2United States;Belgium